These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19192640)

  • 41. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
    Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
    Asayama M; Fuse N; Yoshino T; Yano T; Tahara M; Doi T; Fujii S; Ohtsu A
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1325-30. PubMed ID: 21461890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
    Asao T; Nokihara H; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Yamamoto N; Sekine I; Kunitoh H; Fujiwara Y; Ohe Y
    Jpn J Clin Oncol; 2015 Oct; 45(10):941-6. PubMed ID: 26232449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.
    Ebata T; Shimoi T; Ishiwata T; Iwasawa S; Bun S; Yunokawa M; Yonemori K; Takiguchi Y; Tamura K
    Oncology; 2017; 93(3):177-182. PubMed ID: 28521313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
    Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
    Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.
    Sakurai R; Kaira K; Miura Y; Sunaga N; Saito R; Oyama T; Hisada T; Yamada M
    Thorac Cancer; 2020 Feb; 11(2):426-435. PubMed ID: 31901017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amrubicin for non-small-cell lung cancer and small-cell lung cancer.
    Kurata T; Okamoto I; Tamura K; Fukuoka M
    Invest New Drugs; 2007 Oct; 25(5):499-504. PubMed ID: 17628745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A case of small cell lung cancer under hemodialysis with chronic renal failure treated with amrubicin while measuring blood concentration of the drug].
    Goto N; Shibuya H; Har K; Hisada T
    Nihon Kokyuki Gakkai Zasshi; 2007 Apr; 45(4):337-43. PubMed ID: 17491313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC.
    Imai H; Kaira K; Naruse I; Kasahara N; Kamide Y; Ono A; Masuda T; Sunaga N; Minato K; Hisada T
    Anticancer Res; 2020 Mar; 40(3):1571-1578. PubMed ID: 32132059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is"chemobrain" a transient state? A prospective pilot study among persons with non-small cell lung cancer.
    Whitney KA; Lysaker PH; Steiner AR; Hook JN; Estes DD; Hanna NH
    J Support Oncol; 2008; 6(7):313-21. PubMed ID: 18847074
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.
    Harada T; Oizumi S; Ito K; Takamura K; Kikuchi E; Kuda T; Sugawara S; Suzuki A; Maemondo M; Fujita Y; Kinoshita I; Inoue A; Hommura F; Katsuura Y; Dosaka-Akita H; Isobe H; Nishimura M;
    Oncologist; 2013; 18(4):439-45. PubMed ID: 23442308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe interstitial lung disease associated with amrubicin treatment.
    Yoh K; Kenmotsu H; Yamaguchi Y; Kubota K; Ohmatsu H; Goto K; Niho S; Ohe Y; Saijo N; Nishiwaki Y
    J Thorac Oncol; 2010 Sep; 5(9):1435-8. PubMed ID: 20683210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amrubicin for the treatment of advanced lung cancer.
    Kurata T
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):171-80. PubMed ID: 19239396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer.
    Watanabe H; Ikesue H; Oshiro M; Nagata K; Mishima K; Takada A; Suetsugu K; Sueyasu M; Egashira N; Harada T; Takayama K; Nakanishi Y; Oishi R
    Chemotherapy; 2012; 58(6):419-25. PubMed ID: 23295219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Early phase II study of amrubicin (SM-5887) for superficial bladder cancer: a dose-finding study for intravesical chemotherapy].
    Tsushima T; Kobashi K; Akebi N; Yamato T; Asahi T; Maki Y; Ohmori H
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):483-91. PubMed ID: 11329782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug delivery and toxicity of adjuvant chemotherapy for non-small cell lung cancer (NSCLC): Washington University experience.
    Velcheti V; Viswanathan AK; Baggstrom MQ; Govindan R
    Acta Oncol; 2007; 46(6):869-70. PubMed ID: 17653916
    [No Abstract]   [Full Text] [Related]  

  • 57. [A case of relapsed small-cell lung cancer successfully treated by administration of amrubicin].
    Mori H; Tanaka H
    Nihon Kokyuki Gakkai Zasshi; 2007 Dec; 45(12):967-70. PubMed ID: 18186244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
    Sone H; Igawa S; Kasajima M; Ishihara M; Hiyoshi Y; Hosotani S; Ohe S; Ito H; Kaizuka N; Manaka H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Thorac Cancer; 2018 Oct; 9(10):1279-1284. PubMed ID: 30126051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin.
    Imai H; Kaira K; Mori K; Watase N; Hisada T; Yamada M; Minato K
    J Cancer Res Ther; 2020; 16(4):764-770. PubMed ID: 32930116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
    Miura Y; Kaira K; Sakurai R; Sunaga N; Saito R; Hisada T; Yamada M
    Lung Cancer; 2018 Jan; 115():42-48. PubMed ID: 29290260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.